Clinical Trial Update: The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating INZ-701 for ENPP1 deficiency in children, with ongoing status (ACTIVE_NOT_RECRUITING).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Hypophosphatemic Rickets
• Enpp1 Deficiency
• Generalized Arterial Calcification of Infancy

Drugs mentioned

• INZ-701

Snippet

Sponsor: Inozyme Pharma | Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 3 | Status: ACTIVE_NOT_RECRUITING